linjc16/ctgov huggingface dataset:
Assessment of Weber Humeral Derotational Osteotomy Using CT Scan

Study Overview
=================
Brief Summary
-----------------
Subjects who have had the Weber osteotomy for Hill-Sachs lesions will have CT of Both shoulders. Amount of rotation in operative shoulder will be compared to contralateral. QOL will be assessed

Official Title
-----------------
Assessment of Weber Humeral Derotational Osteotomy Using CT Scan

Conditions
-----------------
Hill Sachs

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who have had the Weber osteotomy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hill Sachs, Weber osteotomy, shoulder dislocation
New CVD Risk Factors for Lowered Cognitive Functioning

Study Overview
=================
Brief Summary
-----------------
To explore the associations between cognitive functioning and three major cardiovascular disease risk factors: high blood pressure; high total plasma homocysteine (tHcy); and ApoE e4 genotype.

Detailed Description
-----------------
BACKGROUND: Arterial hypertension and high blood pressure (HBP) are major risk factors for cardiovascular disease (CVD) and stroke; they are also risk factors for lowered cognitive functioning. Except for diabetes, there have been comparatively few studies of other common risk factors, particularly with regard to interrelationships among risk factors which may adversely affect cognitive ability. DESIGN NARRATIVE: The study examines associations between cognitive functioning and three cardiovascular risk factors: 1) high blood pressure; 2) high total plasma homocysteine (tHcy), and 3) ApoE e4 genotype. These associations are examined cross-sectionally as well as longitudinally, using data collected at a follow-up visit of members of a cohort that has been followed for the past 18-19 years. Longitudinal data are used to examine both current and change in cognitive functioning. Some analyses are prospective (e.g., high blood pressure and change in cognitive functioning), while others are cross-sectional (e.g., ApoE e4 and current cognitive functioning) or retrospective (e.g., tHcy and change in cognitive functioning). Structural equation models are used to examine cross-sectional data in elucidating a general theoretical model. Two-stage growth curve analyses and survival analyses are appropriate methods for analyzing the longitudinal data. The study includes a very comprehensive set of measures that have already been collected or will be collected during the follow-up visit. All potential confounders of the association between the three target predictor variables and the various domains of cognitive functioning appear to have been included in this design.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension, Neurologic Manifestations

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand nitrous oxide effects in post traumatic stress disorder (PTSD)

Detailed Description
-----------------
Post traumatic stress disorder (PTSD) is a disabling mental health disorder that impacts the lives of individuals. This study aims to understand nitrous oxide's effects in PTSD.

Official Title
-----------------
Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)

Conditions
-----------------
Post Traumatic Stress Disorder

Intervention / Treatment
-----------------
* Drug: Nitrous Oxide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-80 Veterans of the United States Uniformed Services primary diagnosis of PTSD sufficient severity of PTSD symptoms fluency in English capacity to provide informed consent Exclusion Criteria: psychiatric or medical conditions that make participation unsafe pregnant or nursing females allergy to nitrous oxide

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nitrous Oxide<br>PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour | Drug: Nitrous Oxide<br>* One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients Who Met and Exceeded Response Criteria of Clinician Administered PTSD Scale for DSM-5 (CAPS-5) | Patients given CAPS-5 (Clinician Administered PTSD Scale for DSM-5), a 30-item structured interview that can be used to assess PTSD symptoms over the past week. For the CAPS-5 the minimum units are 0 and maximum units on the total scale are 80. The higher the number on the CAPS-5, the more severe the symptoms. Response was defined as at least a 12 point reduction on the CAPS-5 | Baseline and 1 week post inhalation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PTSD
Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

Study Overview
=================
Brief Summary
-----------------
Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-hodgkin's lymphoma confined to the central nervous system. It accounts for about 4% of all intracranial tumors and 4% to 6% of all non-Hodgkin's lymphomas . Among them, the most common type is diffuse large B cell lymphoma (DLBCL), accounting for about 95% of all cases. High dose methotrexate (HD-MTX) based chemotherapy can improve the prognosis of patients, but only 30% to 40% of patients can achieve sustained remission, and the overall prognosis is very poor[4, 6]. Currently, the International Extranodal Lymphoma Study Group (IESLG) prognostic scoring system and the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic index are widely used to evaluate the prognosis in patients with PCNSL. However, IESLG model has some limitations such as the relatively small number of patients and short follow-up period. MSKCC model may have an inherent selection bias because retrospective data were collected from a single large institution. Therefore, there is a urgent need to identify novel indicators for prognosis evaluation and risk stratification in PCNSL patients.

Official Title
-----------------
Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

Conditions
-----------------
PCNSL, Survival Analysis

Intervention / Treatment
-----------------
* Other: prognostic marker


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (i)The pathological biopsy and immunohistochemistry diagnosis were PCNSL according to WHO diagnostic criteria for PCNSL in 2016. (ii) No treatment has been received. (iii)There were no diseases with malignant tumor, serious infection, other blood system diseases, immune system diseases and other conditions which may have great influence on peripheral blood lymphocyte count. (iv) The clinical data were complete. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: prognostic marker|prognostic marker|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | from the date of diagnosis to death from any cause or to the date of last follow-up | from September 1, 2013 to June 1, 2020 |
A Global Active Surveillance for Community Acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia.

Official Title
-----------------
Global Active Surveillance for Community-Acquired Pneumonia (CAP) in Adults 50 Years and Older

Conditions
-----------------
Community Acquired Pneumonia

Intervention / Treatment
-----------------
* Procedure: Blood draw
* Procedure: Chest X-ray
* Procedure: urine specimen
* Procedure: Nasopharyngeal swab
* Procedure: sputum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult subjects 50 years of age or older Subject must reside in the surveillance area Subjects who present to a study healthcare facility where the treating physician clinically suspects CAP Exclusion Criteria: Any subject who is transferred to a study healthcare facility after already being hospitalized for 48 hours or more at any other in-patient facility (such as a community hospital). Hospital Acquired pneumonia (ie, develops signs and symptoms of pneumonia after being hospitalized for 48 hours or more).

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Subjects with Community-Acquired Pneumonia<br>Subjects with Community-Acquired Pneumonia | Procedure: Blood draw<br>* culture for Streptococcus pneumoniae Frequency-1<br>* Other names: Blood stick;Procedure: Chest X-ray<br>* image of the lungs to assess changes consistent with pneumonia Frequency-1<br>* Other names: Picture of lungs;Procedure: urine specimen<br>* assay for the presence of Streptococcus pneumoniae Binax and UAD<br>* Other names: urine dipstick test;Procedure: Nasopharyngeal swab<br>* culture for Streptococcus pneumoniae Frequency-1<br>* Other names: swab from inside the nose and throat;Procedure: sputum<br>* culture for Streptococcus pneumoniae Frequency-1<br>* Other names: collection secretions produced during cough;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence rates of CAP in adults 50 years and older |  | up to 120 days from enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of bacterial agents associated with CAP, Case fatality and incidence rates of CAP number and characteristics of subjects from outpatient clinics, emergency rooms, and hospital in-patient departments |  | up to 120 days from enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CAP
INSURE: INcidence Free SUrvival Before and After Implantable Cardioverter Defibrillator (ICD) Replacement

Study Overview
=================
Brief Summary
-----------------
The INSURE trial is a multi-center, prospective trial to collect information about adequate ICD therapies in ICD patients before and after their first elective ICD replacement.

Detailed Description
-----------------
The INSURE trial is a multi-center, prospective trial to collect information about adequate ICD therapies in ICD patients before & after their first elective ICD replacement. For this purpose all consecutive ICD patients will be included in the study, whose first implanted device is replaced due to ICD battery depletion (i.e. arrival at battery indicator ERI). ICD replacements due to other reasons can be included if duration of first ICD implantation was > 3 years. All patients included in the trial are regularly followed up until delivery of their first adequate ICD therapy. The collected data shall provide statistically valid information about the risk to patients who never have experienced adequate ICD therapy before the ICD replacement investigated in this study. In the future, these statistical risk data can give additional information to implanting physicians, such as whether an ICD replacement can eventually be omitted in those patients who are at very low risk for the occurrence of ICD therapies. All actually available GUIDANT ICDs with CE certificate can be implanted in this trial.

Official Title
-----------------
INcidence Free SUrvival Before and After ICD Replacement

Conditions
-----------------
Ventricular Fibrillation

Intervention / Treatment
-----------------
* Device: ICD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All elective ICD replacements due to battery depletion of the first ICD being implanted in the patient Exclusion Criteria: Non-availability to regular follow-up Age < 18 years Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ICD|all models of Guidant/Bsc ICD's|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Weight in Lower Limbs Improves Gait Ataxia of in Machado-Joseph Disease Patients

Study Overview
=================
Brief Summary
-----------------
Few studies evaluated the efficacy of adding weights on the lower limbs in patients with ataxic disorders. There is no current evidence on which would be the most appropriate weight for use in this context. To assess progress and benefits of using this load, gait of symptomatic carriers of spinocerebellar ataxia type 3/Machado Joseph disease the objective of the study is to evaluate the gait with and without different load weights on lower limbs. Outcomes were the Scale for the Assessment and Ataxia Rating of (SARA), kinematic gait assessment by the accelerometer and gyroscope and the Patient Global Impression (PGI) about which weight they prefer for walking.

Official Title
-----------------
Weight in Lower Limbs Improves Gait Ataxia Of in Machado-Joseph Disease Patients: A Randomized Crossover Trial

Conditions
-----------------
Machado-Joseph Disease

Intervention / Treatment
-----------------
* Device: Weight in Lower Limbs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients should have between 18 and 65 years of age and independent gait Exclusion Criteria: Were the need of assistive devices for walking ≤ 10m (such as crutches, wheelchairs and orthotics) Item gait of Scale for the Assessment and Rating of Ataxia (SARA)19≥, presence of other neurological disease that affect motor system Orthopedic impairments of lower limbs (fractures or surgeries in the past 6 months) Difference between the lower limbs greater than 3.0 cm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo Weight in Lower Limbs<br>placebo Weight in Lower Limbs | Device: Weight in Lower Limbs<br> <br> |
| Other: 0,5 kg Weight in Lower Limbs<br>0,5 kg Weight in Lower Limbs | Device: Weight in Lower Limbs<br> <br> |
| Other: 1,0 kg Weight in Lower Limbs<br>1,0 kg Weight in Lower Limbs | Device: Weight in Lower Limbs<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gait speed analysis [speed (mt/min) of walking for 10 meters away] |  | speed (mt/min) of walking for 10 meters away in 1min timeout | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gait cadence analysis [cadence (steps/min) of walking for 10 meters away] |  | cadence (steps/min) of walking for 10 meters away in 1min timeout | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SCA 3, Ataxic Gait
Ramipril - Hypertension

Study Overview
=================
Brief Summary
-----------------
Primary objective: Mean values of systolic and diastolic office blood pressure Secondary objectives: Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

Official Title
-----------------
Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Ramipril


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no previous antihypertensive therapy high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg) Exclusion Criteria: antihypertensive therapy blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ramipril|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean systolic and diastolic 24-hour blood pressure in ABPM |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall mortality and total number of cardiovascular and cerebro-vascular events |  |  | 
| Changes in mean blood pressure readings over time |  |  | 
| Reasons for admissions to hospital/-stays |  |  | 
| Occurrence of pathological fasting glucose levels in serum/pathological HbA1c levels. |  |  |
National Survey on Dyslipidemic Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.

Official Title
-----------------
Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.

Conditions
-----------------
Dyslipidemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of dyslipemia made less than 2 years Treated by a lipid-lowering drug Agree to take part in the survey Exclusion Criteria: Patient included in a clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention). |  | Once | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
time to lipid-lowering drug implementation, dyslipidemic patients
Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure

Study Overview
=================
Brief Summary
-----------------
This study proposes to examine the correlation of central venous pressure to measures of the diameter of the inferior vena cava as determined by bedside ultrasonography.

Detailed Description
-----------------
Central venous pressure (CVP) is a key physiologic estimate of preload, which in turn helps define the vascular fluid status. It is a particularly important parameter to measure in critically ill and injured patients who may require resuscitation. Unfortunately, measurement of the CVP requires invasive central venous catheters which can be difficult or time-consuming to insert. A non-invasive means of inferring the CVP would provide clinicians with an alternative. Preliminary data suggests that the diameter of the vena cava may reflect the CVP. Ultrasonography can provide reliable measures of internal body structures including the vena cava, and therefore may be useful in this regard. Collecting simultaneous values of vena cava diameter and CVPs will allow for the identification and quantification of correlation.

Official Title
-----------------
Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure

Conditions
-----------------
Shock, Hypovolemia, Hypervolemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CVP or right heart catheter that is already in place and functioning properly Exclusion Criteria: Supine position or placement of ultrasound probe on abdomen is contraindicated.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bedside ultrasound measurement of the diameter of the inferior vena cava and simultaneously measured central venous pressure. |  | Cross-sectional | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anatomic view and phase of respiration at the time of measurements. |  | Cross-sectional | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrasonography, Central Venous Pressure, Noninvasive monitoring, Shock, Resuscitation